Combating Pseudomonas aeruginosa infections with antimicrobial peptide carriers The bacterium Pseudomonas aeruginosa is a leading cause of hospital-acquired infections, including ventilator-associated pneumonia and sepsis. This pathogen exacerbates the condition of already compromised patients and exhibits high resistance to antibiotics, posing a significant challenge in healthcare settings. Our innovative project aims to combat P. aeruginosa through a novel approach involving carriers for antimicrobial peptides (AMPs). The primary objective is to ensure the effective delivery of potent AMPs directly into the bacterial cells, thereby maximizing their antimicrobial activity.